Additionally, combining immunotherapy with other treatments, such as chemotherapy and antiangiogenic therapy, could be a future direction for SCLC treatment, as it has shown potential in the treatment of EGFR-mutant adenocarcinoma and classical SCLC [87]. This evidence concerns the gene EGFR and small cell lung carcinoma.